Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Transitional Cell | 3 | 2024 | 24 | 2.000 |
Why?
|
| Kidney Neoplasms | 4 | 2022 | 114 | 1.840 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 62 | 1.750 |
Why?
|
| Neoplasms | 5 | 2023 | 1261 | 1.360 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 75 | 1.330 |
Why?
|
| Immunotherapy | 3 | 2024 | 237 | 1.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 225 | 1.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2018 | 33 | 1.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 200 | 0.810 |
Why?
|
| Catheter Ablation | 1 | 2022 | 141 | 0.730 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 171 | 0.630 |
Why?
|
| Telemedicine | 1 | 2023 | 336 | 0.590 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 577 | 0.540 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 138 | 0.420 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 144 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 405 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2013 | 251 | 0.340 |
Why?
|
| Humans | 13 | 2024 | 60132 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 302 | 0.260 |
Why?
|
| Disease-Free Survival | 1 | 2024 | 233 | 0.230 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 42 | 0.230 |
Why?
|
| Perioperative Care | 1 | 2024 | 79 | 0.220 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 29 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 118 | 0.220 |
Why?
|
| Safety-net Providers | 1 | 2023 | 34 | 0.210 |
Why?
|
| Microwaves | 1 | 2022 | 15 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 647 | 0.190 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 12 | 0.180 |
Why?
|
| Hematuria | 1 | 2021 | 20 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.180 |
Why?
|
| Nephrectomy | 1 | 2021 | 49 | 0.180 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 42 | 0.180 |
Why?
|
| Female | 7 | 2023 | 31250 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2021 | 61 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 792 | 0.170 |
Why?
|
| Decision Making | 1 | 2023 | 394 | 0.160 |
Why?
|
| Palliative Care | 1 | 2021 | 215 | 0.160 |
Why?
|
| Vaccination | 1 | 2021 | 344 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 629 | 0.150 |
Why?
|
| Watchful Waiting | 1 | 2018 | 24 | 0.150 |
Why?
|
| Withholding Treatment | 1 | 2018 | 38 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 558 | 0.130 |
Why?
|
| Pregnancy | 1 | 2023 | 2367 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 324 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2022 | 5262 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2014 | 6 | 0.120 |
Why?
|
| Gastrointestinal Hormones | 1 | 2014 | 10 | 0.120 |
Why?
|
| Middle Aged | 5 | 2021 | 16535 | 0.110 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2014 | 15 | 0.110 |
Why?
|
| Pyrroles | 1 | 2014 | 50 | 0.110 |
Why?
|
| Bevacizumab | 1 | 2014 | 57 | 0.110 |
Why?
|
| Neuropeptides | 1 | 2014 | 82 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2014 | 65 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 102 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 78 | 0.110 |
Why?
|
| Indazoles | 1 | 2013 | 12 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 35 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6139 | 0.100 |
Why?
|
| Immune System | 1 | 2014 | 129 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 196 | 0.100 |
Why?
|
| Imidazoles | 1 | 2013 | 83 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2014 | 177 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 281 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Cytokines | 1 | 2014 | 911 | 0.080 |
Why?
|
| Male | 4 | 2021 | 27971 | 0.080 |
Why?
|
| Aged | 3 | 2021 | 13581 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1213 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 327 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 4396 | 0.070 |
Why?
|
| Adolescent | 1 | 2018 | 5958 | 0.070 |
Why?
|
| Animals | 2 | 2014 | 19768 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 910 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1132 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 80 | 0.050 |
Why?
|
| Adult | 1 | 2018 | 15985 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5197 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 172 | 0.040 |
Why?
|
| Mice | 1 | 2014 | 10343 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 118 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 75 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 1591 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2362 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 25 | 0.020 |
Why?
|
| Nitriles | 1 | 2011 | 62 | 0.020 |
Why?
|
| Triazoles | 1 | 2011 | 52 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 109 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 125 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 196 | 0.020 |
Why?
|